FINRA Considering Revised Rules For High Risk Brokers

Financial industry regulators are seeking to put tougher rules in place to oversee the outside business activities of brokers and dealers, which could pose a risk to investors. 

As part of an ongoing review of its practices, the Financial Industry Regulatory Authority (FINRA) issued a regulatory notice (PDF) this month, which seeks comments on existing and proposed regulations design to oversee activities by broker-dealers outside of their firms. Comments are being taken until June 29, 2017.

“These rules were designed to protect investors from potentially problematic or risky activities that are unknown to the firm but could be perceived by the investing public as either part of the firm’s business or having the firm’s imprimatur,” FINRA explained in a press release. “In addition, the rules protect firms from reputational or litigation risks when employees engage in business and securities activities outside of the firm.”

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

FINRA is a non-governmental agency that oversees the financial industry, which is designed to provide investor protection and market integrity by writing and enforcing rules that govern the activities of 3,800 broker-dealers and more than 633,000 brokers.

The group is seeking feedback on how the current rules have performed thus far, and proposes changes that could increase sanctions against broker-dealers who take high-risk actions outside of their firm that could threaten their investors, could restrict some activities by firms, and could allow FINRA to level more severe disciplinary actions against broker-dealers who have a history of misconduct.

The proposed rule changes would also let FINRA disclose when a firm has increased requirements, such as mandatory recording of customer telephone conversations, due to a high amount of employees who have faced disciplinary action from FINRA.

The review and potential changes are part of what is called the FINRA360 Initiative. The initiative seeks to review all of FINRA’s operations and programs.

“Regularly reviewing significant rules to ensure they remain effective at protecting investors in an efficient manner is a key priority that aligns with our FINRA360 Initiative,” FINRA President and CEO Robert W. Cook said in the press release. “Successful self-regulation requires continuous renewal

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted 2 days ago)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted 3 days ago)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted 4 days ago)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.